Abstract
Diseases caused by protozoan parasites are still an important health problem. These parasites can cause a wide spectrum of diseases, some of which are severe and have high morbidity or mortality if untreated. Since they are still uncontrolled, it is important to find novel drug targets and develop new therapies to decrease their remarkable social and economic impact on human societies. In the past years, human HSP90 has become an interesting drug target that has led to a large number of investigations both at state organizations and pharmaceutical companies, followed by clinical trials. The finding that HSP90 has important biological roles in some protozoan parasites like Plasmodium spp, Toxoplasma gondii and trypanosomatids has allowed the expansion of the results obtained in human cancer to these infections. This review summarizes the latest important findings showing protozoan HSP90 as a drug target and presents three patents targeting T. gondii, P. falciparum and trypanosomatids HSP90.
Keywords: Plasmodium, Toxoplasma, HSP90, geldanamycin, 17-AAG, patent, therapy
Recent Patents on Biotechnology
Title:A Review of Recent Patents on the Protozoan Parasite HSP90 as a Drug Target
Volume: 7 Issue: 1
Author(s): Sergio O. Angel, Mariana Matrajt and Pablo C. Echeverria
Affiliation:
Keywords: Plasmodium, Toxoplasma, HSP90, geldanamycin, 17-AAG, patent, therapy
Abstract: Diseases caused by protozoan parasites are still an important health problem. These parasites can cause a wide spectrum of diseases, some of which are severe and have high morbidity or mortality if untreated. Since they are still uncontrolled, it is important to find novel drug targets and develop new therapies to decrease their remarkable social and economic impact on human societies. In the past years, human HSP90 has become an interesting drug target that has led to a large number of investigations both at state organizations and pharmaceutical companies, followed by clinical trials. The finding that HSP90 has important biological roles in some protozoan parasites like Plasmodium spp, Toxoplasma gondii and trypanosomatids has allowed the expansion of the results obtained in human cancer to these infections. This review summarizes the latest important findings showing protozoan HSP90 as a drug target and presents three patents targeting T. gondii, P. falciparum and trypanosomatids HSP90.
Export Options
About this article
Cite this article as:
O. Angel Sergio, Matrajt Mariana and C. Echeverria Pablo, A Review of Recent Patents on the Protozoan Parasite HSP90 as a Drug Target, Recent Patents on Biotechnology 2013; 7 (1) . https://dx.doi.org/10.2174/1872208311307010002
DOI https://dx.doi.org/10.2174/1872208311307010002 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry Vaccine Safety Monitoring Systems in Developing Countries: An Example of the Vietnam Model
Current Drug Safety Recent Patents on Alphavirus Protein Expression and Vector Production
Recent Patents on Biotechnology Vaccines for Patients with COPD
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Water in the Brain: Role of Aquaporin-4 in Ischemic Brain Edema
Current Drug Targets Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Immunomodulatory Properties of Farnesoids: The New Steroids?
Current Medicinal Chemistry Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology A Review of Nanocarrier-Based CNS Delivery Systems
Current Drug Delivery Impairment of T Cell Immunity by the Respiratory Syncytial Virus: Targeting Virulence Mechanisms for Therapy and Prophylaxis
Current Medicinal Chemistry The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies HIV-1 Induced CNS Dysfunction: Current Overview and Research Priorities
Current HIV Research Playing with Fire: Manipulation of Macrophage Proinflammatory Signal Transduction by the Intracellular Protozoan Toxoplasma gondii
Current Immunology Reviews (Discontinued) Molecular and Biological Aspects of the Bovine Immunodeficiency Virus
Current HIV Research Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Antibody Responses, Amyloid-β Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial
CNS & Neurological Disorders - Drug Targets